Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRP-guided therapy with LiPlaCis, 2X-121, or Irofulven in pre-treated solid tumors (phase II basket)
2019-002071-34Phase 2Terminated
- Sponsor
- Vejle Hospital
- Start
- Jun 2019
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of liplacis, stenoparib and irofulven in breast cancer, ovarian cancer, bronchial carcinoma and 3 more (3 arms), sponsored by Vejle Hospital. Primary endpoint: Primary anti-cancer effect of DRP-directed therapy (phase II basket). Started Jun 2019; status: terminated.
02
Drugs
liplacisstenoparibirofulven
03
Conditions
breast cancerovarian cancerbronchial carcinomaprostate cancer (PCa)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-002071-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002071-34.